bioAffinity Technologies, Inc. (BIAF) is a publicly traded company in the Healthcare sector, operating within the Medical - Diagnostics & Research industry. The company is headquartered in San Antonio, TX, United States. The current CEO is Maria Zannes.
BIAF has IPO date of 2022-09-01, 57 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $12.64M.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
